[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE037575T2 - Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot - Google Patents

Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot

Info

Publication number
HUE037575T2
HUE037575T2 HUE12831417A HUE12831417A HUE037575T2 HU E037575 T2 HUE037575 T2 HU E037575T2 HU E12831417 A HUE12831417 A HU E12831417A HU E12831417 A HUE12831417 A HU E12831417A HU E037575 T2 HUE037575 T2 HU E037575T2
Authority
HU
Hungary
Prior art keywords
cyclopolysaccharide
pharmaceutical composition
hdac inhibitor
hdac
inhibitor
Prior art date
Application number
HUE12831417A
Other languages
English (en)
Inventor
Yu Chen
Lan Yang
Feiyu Feng
Qiufu Ge
Dianwu Guo
Yi Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of HUE037575T2 publication Critical patent/HUE037575T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HUE12831417A 2011-09-18 2012-09-14 Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot HUE037575T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536038P 2011-09-18 2011-09-18
US201261602408P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
HUE037575T2 true HUE037575T2 (hu) 2018-09-28

Family

ID=47883974

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12831417A HUE037575T2 (hu) 2011-09-18 2012-09-14 Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot

Country Status (40)

Country Link
US (1) US9376395B2 (hu)
EP (2) EP2758052B9 (hu)
JP (2) JP2014526512A (hu)
KR (2) KR20140078619A (hu)
CN (1) CN103826630B (hu)
AP (1) AP3656A (hu)
AR (1) AR087909A1 (hu)
AU (1) AU2012308453B2 (hu)
BR (1) BR112014006271B1 (hu)
CA (1) CA2847842C (hu)
CL (1) CL2014000645A1 (hu)
CO (1) CO6930367A2 (hu)
CR (1) CR20140134A (hu)
CY (1) CY1120080T1 (hu)
DK (1) DK2758052T3 (hu)
DO (1) DOP2014000048A (hu)
EA (1) EA028413B1 (hu)
EC (1) ECSP14013239A (hu)
ES (2) ES2662775T3 (hu)
GT (1) GT201400069A (hu)
HK (2) HK1199824A1 (hu)
HR (1) HRP20180690T1 (hu)
HU (1) HUE037575T2 (hu)
IL (1) IL230838A (hu)
LT (1) LT2758052T (hu)
ME (1) ME03088B (hu)
MX (1) MX346432B (hu)
MY (1) MY169495A (hu)
NI (1) NI201400022A (hu)
NZ (1) NZ621386A (hu)
PE (1) PE20141552A1 (hu)
PL (1) PL2758052T3 (hu)
PT (1) PT2758052T (hu)
RS (1) RS57063B1 (hu)
SI (1) SI2758052T1 (hu)
TN (1) TN2014000095A1 (hu)
TW (1) TWI583382B (hu)
UA (1) UA116333C2 (hu)
WO (1) WO2013040286A2 (hu)
ZA (1) ZA201401676B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CA2925546C (en) 2012-10-29 2022-06-14 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP2017537164A (ja) * 2014-12-05 2017-12-14 ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
CN106580971B (zh) * 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 一种药物组合物及其制备方法
EP4321513A3 (en) 2016-03-28 2024-05-08 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
JP6770986B2 (ja) 2018-03-06 2020-10-21 日本電産モビリティ株式会社 誘導性負荷制御装置
MX2021000127A (es) 2018-06-29 2021-03-29 Incyte Corp Formulaciones de un inhibidor de axl/mer.
CA3124005A1 (en) * 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating multiple myeloma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376A (en) 1847-11-20 Improvement in bog-cutters
US645A (en) 1838-03-17 Back for poeges and fetrnages
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AU750207B2 (en) 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
AU2004215624B2 (en) 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
EA018982B1 (ru) * 2005-05-13 2013-12-30 Топотаргет Юкей Лимитед Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
WO2008067027A2 (en) * 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2326306A1 (en) * 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
CN102186842B (zh) * 2009-01-23 2014-07-23 杭州民生药业有限公司 异羟肟酸衍生物
JP5654498B2 (ja) * 2009-02-25 2015-01-14 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
CN101928234B (zh) * 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-(杂)芳基-n-羟基己/庚酰胺化合物及其制备方法
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102993102B (zh) * 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n,n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法

Also Published As

Publication number Publication date
RS57063B1 (sr) 2018-06-29
EP2758052A2 (en) 2014-07-30
KR102048079B1 (ko) 2019-11-22
CA2847842C (en) 2019-12-31
CN103826630B (zh) 2016-12-07
DK2758052T3 (en) 2018-05-28
EP2758052B1 (en) 2018-02-14
ES2662775T9 (es) 2019-05-16
MX2014003283A (es) 2014-05-21
TW201316986A (zh) 2013-05-01
HK1199824A1 (en) 2015-07-24
TN2014000095A1 (en) 2015-07-01
EP3318284A1 (en) 2018-05-09
NZ621386A (en) 2015-05-29
KR20190110148A (ko) 2019-09-27
DOP2014000048A (es) 2014-06-30
SI2758052T1 (en) 2018-05-31
WO2013040286A2 (en) 2013-03-21
US20150183747A1 (en) 2015-07-02
CY1120080T1 (el) 2018-12-12
US9376395B2 (en) 2016-06-28
HK1253692A1 (zh) 2019-06-28
LT2758052T (lt) 2018-04-10
IL230838A0 (en) 2014-03-31
GT201400069A (es) 2015-07-13
KR20140078619A (ko) 2014-06-25
EP2758052B9 (en) 2019-03-27
AP2014007498A0 (en) 2014-03-31
EA028413B1 (ru) 2017-11-30
PL2758052T3 (pl) 2018-10-31
EP2758052A4 (en) 2015-05-27
EP3318284B1 (en) 2022-01-26
IL230838A (en) 2017-02-28
NI201400022A (es) 2014-04-23
ME03088B (me) 2019-01-20
PE20141552A1 (es) 2014-11-08
TWI583382B (zh) 2017-05-21
CN103826630A (zh) 2014-05-28
CR20140134A (es) 2014-05-15
CA2847842A1 (en) 2013-03-21
EA201490650A1 (ru) 2014-06-30
HRP20180690T1 (hr) 2018-06-29
AU2012308453B2 (en) 2016-11-10
CO6930367A2 (es) 2014-04-28
ES2911427T3 (es) 2022-05-19
MX346432B (es) 2017-03-21
JP2018039848A (ja) 2018-03-15
AU2012308453A1 (en) 2014-03-06
AR087909A1 (es) 2014-04-23
CL2014000645A1 (es) 2014-10-03
PT2758052T (pt) 2018-03-29
MY169495A (en) 2019-04-15
ZA201401676B (en) 2017-01-25
ES2662775T3 (es) 2018-04-09
JP2014526512A (ja) 2014-10-06
ECSP14013239A (es) 2014-07-31
JP6557318B2 (ja) 2019-08-07
WO2013040286A3 (en) 2013-05-10
BR112014006271A2 (pt) 2017-04-11
BR112014006271B1 (pt) 2022-03-22
AP3656A (en) 2016-04-04
UA116333C2 (uk) 2018-03-12

Similar Documents

Publication Publication Date Title
HK1253692A1 (zh) 含有hdac抑制劑和環多醣的藥物組合物
HK1215948A1 (zh) 醯胺及其醫藥用途
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
EP2771321A4 (en) HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
EP2721031A4 (en) BROMODOMA INHIBITORS AND ITS USE
EP2705039A4 (en) BROMODOMAIN INHIBITORS AND USES THEREOF
HK1189587A1 (en) Bromodomain inhibitors and uses thereof
EP2663312A4 (en) IRAQ INHIBITORS AND THEIR USE
HK1198827A1 (en) Dyrk1 inhibitors and uses thereof dyrk1
EP2571352A4 (en) SELECTIVE HDAC HEMMER
ZA201307956B (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
EP2623556A4 (en) DRIP AND RESIN CONNECTION
EP2688572A4 (en) PHARMACEUTICAL COMPOSITION USING A HDAC HEMMER AND STEROID, AND USE THEREOF
HK1152485A1 (en) A pharmaceutical composition comprising l-carnitine and dobesilate
ZA201304633B (en) A pharmaceutical composition
EP2775831A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
SI2753313T1 (sl) Farmacevtski sestavki, ki obsegajo inhibitor aromataze
PL2659889T3 (pl) Kompozycja przeciwgorączkowa/przeciwbólowa
HRP20141173T1 (hr) Medikament koji sadrži miramistin
ZA201205684B (en) Ester compound and use thereof
ZA201201003B (en) A pharmaceutical composition
EP2784065A4 (en) GLYCINE REUPTAKE INHIBITOR AND USE THEREOF
GB201110598D0 (en) Pharmaceutical compositions and devices
GB201018597D0 (en) Inhibitors